Uniqure Nv (QURE)

$5.65

+1.09

(+23.9%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $4.85
    $5.66
    $5.65
    downward going graph

    14.25%

    Downside

    Day's Volatility :14.4%

    Upside

    0.18%

    downward going graph
  • $3.73
    $11.35
    $5.65
    downward going graph

    33.98%

    Downside

    52 Weeks Volatility :67.14%

    Upside

    50.22%

    downward going graph

Returns

PeriodUniqure NvSector (Health Care)Index (Russel 2000)
3 Months
18.75%
5.7%
0.0%
6 Months
-12.31%
6.7%
0.0%
1 Year
-24.38%
18.4%
0.0%
3 Years
-85.34%
20.8%
-20.2%

Highlights

Market Capitalization
222.1M
Book Value
$1.99
Earnings Per Share (EPS)
-5.92
PEG Ratio
0.0
Wall Street Target Price
19.18
Profit Margin
0.0%
Operating Margin TTM
-425.99%
Return On Assets TTM
-17.12%
Return On Equity TTM
-126.41%
Revenue TTM
27.7M
Revenue Per Share TTM
0.57
Quarterly Revenue Growth YOY
359.4%
Gross Profit TTM
-87.4M
EBITDA
-217.1M
Diluted Eps TTM
-5.92
Quarterly Earnings Growth YOY
-0.18
EPS Estimate Current Year
-4.25
EPS Estimate Next Year
-2.78
EPS Estimate Current Quarter
-1.25
EPS Estimate Next Quarter
-1.2

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Uniqure Nv(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
17
Hold
5
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 239.47%

Current $5.65
Target $19.18

Company Financials

FY18Y/Y Change
Revenue
11.3M
↓ 13.91%
Net Income
-83.3M
↑ 3.63%
Net Profit Margin
-738.25%
↓ 124.92%
FY19Y/Y Change
Revenue
7.3M
↓ 35.48%
Net Income
-128.0M
↑ 53.67%
Net Profit Margin
-1.8K%
↓ 1019.9%
FY20Y/Y Change
Revenue
37.5M
↑ 415.23%
Net Income
-125.0M
↓ 2.33%
Net Profit Margin
-333.27%
↑ 1424.88%
FY21Y/Y Change
Revenue
524.0M
↑ 1296.82%
Net Income
329.6M
↓ 363.62%
Net Profit Margin
62.9%
↑ 396.17%
FY22Y/Y Change
Revenue
106.5M
↓ 79.68%
Net Income
-126.8M
↓ 138.47%
Net Profit Margin
-119.07%
↓ 181.97%
FY23Y/Y Change
Revenue
15.8M
↓ 85.12%
Net Income
-308.5M
↑ 143.3%
Net Profit Margin
-1.9K%
↓ 1828.02%
Q1 FY23Q/Q Change
Revenue
5.3M
↓ 94.82%
Net Income
-77.2M
↓ 1234.52%
Net Profit Margin
-1.5K%
↓ 1456.9%
Q2 FY23Q/Q Change
Revenue
2.4M
↓ 54.52%
Net Income
-68.5M
↓ 11.33%
Net Profit Margin
-2.8K%
↓ 1376.9%
Q3 FY23Q/Q Change
Revenue
1.4M
↓ 41.91%
Net Income
-89.6M
↑ 30.81%
Net Profit Margin
-6.4K%
↓ 3538.93%
Q4 FY23Q/Q Change
Revenue
6.7M
↑ 375.41%
Net Income
-73.2M
↓ 18.27%
Net Profit Margin
-1.1K%
↑ 5271.68%
Q1 FY24Q/Q Change
Revenue
8.5M
↑ 26.85%
Net Income
-65.6M
↓ 10.37%
Net Profit Margin
-773.34%
↑ 321.08%
Q2 FY24Q/Q Change
Revenue
11.1M
↑ 31.13%
Net Income
-56.3M
↓ 14.2%
Net Profit Margin
-506.01%
↑ 267.33%
FY18Y/Y Change
Total Assets
273.9M
↑ 31.13%
Total Liabilities
94.3M
↓ 20.71%
FY19Y/Y Change
Total Assets
448.6M
↑ 63.79%
Total Liabilities
125.6M
↑ 33.16%
FY20Y/Y Change
Total Assets
340.4M
↓ 24.13%
Total Liabilities
96.5M
↓ 23.16%
FY21Y/Y Change
Total Assets
809.2M
↑ 137.72%
Total Liabilities
213.4M
↑ 121.17%
FY22Y/Y Change
Total Assets
705.0M
↓ 12.88%
Total Liabilities
229.0M
↑ 7.29%
FY23Y/Y Change
Total Assets
831.7M
↑ 17.98%
Total Liabilities
624.0M
↑ 172.55%
Q1 FY23Q/Q Change
Total Assets
631.0M
↓ 10.49%
Total Liabilities
218.2M
↓ 4.68%
Q2 FY23Q/Q Change
Total Assets
942.8M
↑ 49.41%
Total Liabilities
589.4M
↑ 170.1%
Q3 FY23Q/Q Change
Total Assets
871.6M
↓ 7.55%
Total Liabilities
602.8M
↑ 2.26%
Q4 FY23Q/Q Change
Total Assets
831.7M
↓ 4.57%
Total Liabilities
624.0M
↑ 3.53%
Q1 FY24Q/Q Change
Total Assets
770.1M
↓ 7.41%
Total Liabilities
623.3M
↓ 0.12%
Q2 FY24Q/Q Change
Total Assets
730.8M
↓ 5.09%
Total Liabilities
633.7M
↑ 1.68%
FY18Y/Y Change
Operating Cash Flow
-76.0M
↑ 18.31%
Investing Cash Flow
-4.2M
↓ 23.97%
Financing Cash Flow
158.0M
↑ 75.37%
FY19Y/Y Change
Operating Cash Flow
-98.7M
↑ 29.78%
Investing Cash Flow
-6.6M
↑ 56.58%
Financing Cash Flow
248.8M
↑ 57.52%
FY20Y/Y Change
Operating Cash Flow
-134.8M
↑ 36.63%
Investing Cash Flow
-9.5M
↑ 42.68%
Financing Cash Flow
7.4M
↓ 97.01%
FY21Y/Y Change
Operating Cash Flow
288.0M
↓ 313.58%
Investing Cash Flow
-67.4M
↑ 610.53%
Financing Cash Flow
94.9M
↑ 1174.29%
FY22Y/Y Change
Operating Cash Flow
-145.1M
↓ 150.38%
Investing Cash Flow
-182.7M
↑ 171.17%
Financing Cash Flow
1.4M
↓ 98.48%
Q1 FY23Q/Q Change
Operating Cash Flow
-78.3M
↑ 43.2%
Investing Cash Flow
3.0M
↓ 101.78%
Financing Cash Flow
131.0K
↓ 78.2%
Q2 FY23Q/Q Change
Operating Cash Flow
-57.0M
↓ 27.21%
Investing Cash Flow
45.8M
↑ 1433.8%
Financing Cash Flow
370.1M
↑ 282447.33%
Q3 FY23Q/Q Change
Operating Cash Flow
38.9M
↓ 168.27%
Investing Cash Flow
-314.1M
↓ 785.28%
Financing Cash Flow
-7.6M
↓ 102.05%

Technicals Summary

Sell

Neutral

Buy

Uniqure Nv is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Uniqure Nv
Uniqure Nv
-15.71%
-12.31%
-24.38%
-85.34%
-89.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-13.97%
8.28%
24.49%
82.67%
258.6%
Novo Nordisk A/s
Novo Nordisk A/s
-14.46%
-7.16%
29.25%
137.43%
348.48%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.47%
77.93%
59.32%
38.21%
249.95%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
12.26%
28.5%
155.67%
163.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Uniqure Nv
Uniqure Nv
2.64
NA
0.0
-4.25
-1.26
-0.17
NA
1.99
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.42
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.7
38.7
1.75
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Uniqure Nv
Uniqure Nv
Buy
$222.1M
-89.32%
2.64
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.7B
258.6%
27.55
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$518.0B
348.48%
38.7
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.9B
249.95%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.3B
163.05%
32.84
-4.74%

Insights on Uniqure Nv

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 1.40M → 11.12M (in $), with an average increase of 41.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -89.57M → -56.29M (in $), with an average increase of 16.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.3% return, outperforming this stock by 83.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.2% return, outperforming this stock by 123.5%

Institutional Holdings

  • Nantahala Capital Management, LLC

    10.89%

  • Vestal Point Capital LP

    9.75%

  • BlackRock Inc

    3.95%

  • 683 Capital Management LLC

    3.90%

  • Schroder Investment Management Group

    3.57%

  • ADAR1 Capital Management LLC

    2.51%

Company Information

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Organization
Uniqure Nv
Employees
480
CEO
Mr. Matthew Craig Kapusta
Industry
Health Technology

Discover More

FAQs